Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway

Figure 1 Effects of empagliflozin on cardiac function in db/db mice. A: M-mode imaging revealed reduced systolic and diastolic function in db/db mice; B: Quantitation of E/A ratio, left ventricular ejection fraction, and left ventricular fractional shortening. NC: Normal control mice; DB: Db/db mice; EM/DB: Db/db mice treated with empagliflozin; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening. ^aP < 0.05 vs NC; ^bP < 0.05 vs DB.